Home-Based Prehabilitation Did Not Reduce Disability or Complications in Older Adults with Frailty: Results of a Pragmatic Multicenter RCT
Posted inAnesthesiology General Surgery news Rehabilitation Medicine

Home-Based Prehabilitation Did Not Reduce Disability or Complications in Older Adults with Frailty: Results of a Pragmatic Multicenter RCT

A pragmatic multicenter randomized trial found that coach-supported, home-based multimodal prehabilitation before elective noncardiac surgery did not reduce 30-day postoperative disability or in-hospital complications in older adults with frailty; higher adherence signaled possible benefit for disability outcomes.
Precision Immunotherapy for Sepsis: ImmunoSep Trial Shows Early Organ‑Function Benefit with Targeted Anakinra or IFN‑γ
Posted inCritical Care Infectious Diseases news

Precision Immunotherapy for Sepsis: ImmunoSep Trial Shows Early Organ‑Function Benefit with Targeted Anakinra or IFN‑γ

The ImmunoSep randomized trial found that biomarker-guided immunotherapy (anakinra for macrophage activation‑like syndrome; interferon‑γ for sepsis‑induced immunoparalysis) improved organ dysfunction by day 9 versus placebo, though 28‑day mortality was unchanged. Safety signals require follow‑up.
Long-Term Nirogacestat for Progressive Desmoid Tumors: Durable Responses, Continued Tumor Shrinkage, and a Manageable Safety Profile
Posted inHematology-Oncology news Oncology

Long-Term Nirogacestat for Progressive Desmoid Tumors: Durable Responses, Continued Tumor Shrinkage, and a Manageable Safety Profile

Extended follow-up from the phase III DeFi trial shows that continuous nirogacestat yields further tumor shrinkage, durable objective responses (ORR 45.7% at up to 4 years), sustained patient-reported benefits, and a consistent, manageable safety profile over a median 33.6 months of exposure.
PASS-01: Gemcitabine/Nab‑Paclitaxel Shows an Overall Survival Edge Over Modified FOLFIRINOX in First‑Line Metastatic PDAC — Biomarker Correlatives Underscore Need to Move Precision Upstream
Posted innews Oncology

PASS-01: Gemcitabine/Nab‑Paclitaxel Shows an Overall Survival Edge Over Modified FOLFIRINOX in First‑Line Metastatic PDAC — Biomarker Correlatives Underscore Need to Move Precision Upstream

In the randomized phase II PASS‑01 trial of first‑line metastatic pancreatic ductal adenocarcinoma (PDAC), progression‑free survival was similar between modified FOLFIRINOX and gemcitabine/nab‑paclitaxel, but overall survival and safety trends favored gemcitabine/nab‑paclitaxel. Molecular profiling and organoid work were feasible but second‑line, correlate‑guided therapy showed limited benefit.
Neoadjuvant 177Lu-PSMA Before SBRT Doubles Progression-Free Survival in Oligorecurrent Hormone-Sensitive Prostate Cancer — Results from the LUNAR Phase II Trial
Posted innews Oncology Urology

Neoadjuvant 177Lu-PSMA Before SBRT Doubles Progression-Free Survival in Oligorecurrent Hormone-Sensitive Prostate Cancer — Results from the LUNAR Phase II Trial

In the randomized phase II LUNAR trial, adding two cycles of neoadjuvant 177Lu-PNT2002 to stereotactic body radiotherapy (SBRT) for oligorecurrent hormone-sensitive prostate cancer significantly prolonged progression-free survival (17.6 vs 7.4 months; HR 0.37) without increased grade ≥3 toxicity.